Journals / KBB-Forum / 2019 / Cilt: 18 - Sayı: 3

PRO-GASTRIN RELEASING PEPTIDE AND NEUTROPHIL-LYMPHOCYTE RATIO IN LARYNGEAL CANCER

LARİNKS KANSERİNDE PRO-GASTRİN SALGILAYAN PEPTİD VE NÖTROFİL-LENFOSİT ORANI

Journal
KBB-Forum
Pages
219–225
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Pro-GRP levels of the malignant group were significantly higher than the benign andcontrol groups (p=0.043; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Pro-gastrin-secreting peptide (pro-GRP) has been identified as a growth factor expressed in many cancer types.
📊
Key Findings & Data:The aim of thisprospective, controlled study was to investigate the relationship between tumor stage and pro-GRP and NLR levels in patients diagnosed with laryngeal SCC.Methods: This study has been conducted on a total of 93 people consisting of 31 healthy individuals, and 62 patients (30 patientsmalign; 32 patients benign) with a laryngeal mass who applied to a tertiary referral center and had surgery.
💡
Conclusion & Impact:Pro-GRP levels of the malignant group were significantly higher than the benign andcontrol groups (p=0.043; p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Pro-gastrin-secreting peptide (pro-GRP) has been identified as a growth factor expressed in many cancer types. Theneutrophil-lymphocyte ratio (NLR) has also been used as a biomarker in patients with squamous cell cancer (SCC). The aim of thisprospective, controlled study was to investigate the relationship between tumor stage and pro-GRP and NLR levels in patients diagnosed with laryngeal SCC.Methods: This study has been conducted on a total of 93 people consisting of 31 healthy individuals, and 62 patients (30 patientsmalign; 32 patients benign) with a laryngeal mass who applied to a tertiary referral center and had surgery. Groups were compared in terms of serum pro-GRP and NLR.Results: The serum pro-GRP values of the malignant, benign and control groups were 17.31±3.30; 15:51±2.87; 14.07±2.43, while theNLR value was 2.99±1.65; 2.14±0.94; 2.05±0.64. Pro-GRP levels of the malignant group were significantly higher than the benign andcontrol groups (p=0.043; p

Özet

Amaç: Pro-gastrin salgılayan peptit (pro-GRP), birçok kanser türünde eksprese edilen bir büyüme faktörü olarak tanımlanmıştır. Nötrofil-lenfosit oranı (NLR) da skuamöz hücreli kanserli (SCC) hastalarda bir biyobelirteç olarak kullanılmıştır. Bu prospektif, kontrollü çalışmanın amacı, larinks SCC tanısı alan hastalarda tümor evresi ile pro-GRP ve NLR düzeyleri arasındaki ilişkiyi araştırmaktır. Yöntem ve Gereçler: Çalışmaya merkezimizde larinks tümörü nedeniyle opere edilen 62 hasta (30 hasta malign; 32 hasta benign) ile 31 sağlıklı birey dahil edildi. Gruplar arasında serum pro-GRP ve NLR açısından karşılaştırma yapıldı. Bulgular: Malign, benign ve kontrol gruplarının serum pro-GRP değerleri sırasıyla 17.31±3.30; 15.51±2.87; 14.07±2.43'iken, NLR değeri sırasıyla 2.99 ± 1.65; 2.14 ± 0.94; 2.05 ± 0.64'idi. Malign grubun pro-GRP düzeyi benign ve kontrol gruplarına göre istatistiksel olarak anlamlı derecede yüksek bulundu (p=0.043; p

🔖

Cite This Article

ÇANDAR, T., ÖZCAN, M., GÜLER, İ., BAKLACI, D., KUM, R. O., KUZUCU, İ. (2022). PRO-GASTRIN RELEASING PEPTIDE AND NEUTROPHIL-LYMPHOCYTE RATIO IN LARYNGEAL CANCER. KBB-Forum, Cilt: 18 - Sayı: 3, 219–225. https://ajindex.com/articles/573084

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA. Biological significance of c-erb B family oncogenes in head and neck cancer. Cancer Metastasis Rev 2005;24(1):47-69
  2. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003;25(1):67- 73
  3. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer2005;114(5):806-816
  4. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824-832
  5. Spindel ER, Zilberberg MD, Habener JF, Chin WW. Two prohormones for gastrin-releasing peptide are encoded by two mRNAs differing by 19 nucleotides. Proc Natl Acad Sci U S A 1986;83(1):19-23
  6. Lebacq-Verheyden AM, Kasprzyk PG, Raum MG, Van WykeCoelingh K, Lebacq JA, Battey JF. Posttranslational processing of endogenous and of baculovirus-expressed human gastrin-releasing peptide precursor. Mol Cell Biol1988;8(8):3129-3135
  7. Fang MZ, Liu C, Song Y, Yang GY, Nie Y, Liao J, Zhao X, Shimada Y, Wang LD, Yang CS. Over-expression of gastrinreleasing peptide in human esophageal squamous cell carcinomas. Carcinogenesis. 2004;25(6):865-871
  8. Parra-Robert M, Orois A, Augé JM, Halperin I, Filella X, Molina R. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma. Clin Chem Lab Med2017;55(3):441-446
  9. Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR. Gastrin-releasing peptide receptormediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst 2002;94(5):375-383
  10. Zhang Q, Bhola NE. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther2007;6(4):1414-1424
  11. Kum RO, Ozcan M, Baklaci D, Kum NY, Yilmaz YF, Gungor V, Unal A. Elevated neutrophil-to-lymphocyte ratio in squamous cell carcinoma of larynx compared to benign and precancerous laryngeal lesions. Asian Pac J Cancer Prev 2014;15(17):7351-7355
  12. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K,Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M. Pretreatment neutrophil count as an independent prognostic factor in advanced non